Don't Routinely Recommend Probuphine for Patients With Opioid Use Disorder

January 2019

Probuphine (pro-BYOO-feen) will be the first buprenorphine IMPLANT to treat opioid use disorder.

We're used to seeing sublingual buprenorphine/naloxone combos (Suboxone)...but misuse or diversion can be a problem.

Probuphine only contains buprenorphine...and consists of 4 subdermal rods inserted just under the skin of the inner upper arm.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Practice More Payers Will Recognize Your Value in Improving Patient Care
Diabetes Compare Cardiovascular Benefits of SGLT2 Inhibitors for Type 2 Diabetes
MRSA Don't Suggest MRSA Decolonization for Most Outpatients
Antihypertensives Ease Concerns About Cancer Risk With BP Meds
Oral Health Reset Perceptions About Treating Dental Pain
Opioids Don't Routinely Recommend Probuphine for Patients With Opioid Use Disorder
Venous Thromboembolism Guide Appropriate VTE Prophylaxis After Surgery or Hospitalization
Eczema Think of Fucibet as an Alternative to Fucidin H for Infected Eczema
Antiarrhythmics Take Notice When Patients Are on Amiodarone
Medication Errors Prevent Mix-Ups Between Lamotrigine and Labetalol
Supplements Be Ready for Patients to Ask About Eye Supplements for Blue Light